Prostate cancer is one of the leading causes of male mortality due to cancer and its prevalence is now increasing; therefore, the development of effective new drugs is now required (1). Androgen ablation therapy is usually effective for this cancer at an earlier stage because the tumors typically depend on androgen for development and growth at that period. However, alternative drugs are needed to treat androgenindependent tumors (2). Docetaxel (DTX) is a taxane derivative, widely used anti-microtubule anti-cancer drug, and an effective chemotherapeutic drug for first-line treatment of hormone-refractory prostate cancer (3). Therefore, combination and comparison studies in vitro and in vivo with DTX are vital for developing novel anti-prostate cancer agents.
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DU145 is a human hormone-independent prostate cancer cell line widely used for evaluating novel anti-prostate cancer agents (4) . The inhibitory activity of DTX against DU145 in vitro exhibited a half maximal inhibitory concentration (IC 50 ) of 1.1 nM (Figure 1 ). A xenograft model of DU145 tumor growth in nude mice is useful for evaluating agents that can treat hormone-refractory prostate cancer. However, the dose-dependence of DTX in such xenograft mice has not been reported, even though it is vital for the screening and development of novel anti-prostate cancer drugs. We report the results of a systematic trial on growth suppression of implanted DU145 tumors and sideeffects with DTX in a wide range (0.1-10 mg/kg; subcutaneously (s.c.); in a week) in two models, a xenograft model formed by implantation of a mixture of DU145 cells and Matrigel™ and a model formed by implantation of solid DU145 tumors (Figure 2 ).
Materials and Methods
Cell line and cell culture. The human prostate cancer cell line DU145 was supplied from Riken BioResource Center (#RCB2143), Tsukuba, Japan. The cell line was maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere containing 5% CO 2 .
Inhibition of DU145 growth in vitro by DTX. DTX (#D4102) was purchased from Tokyo Chemical Industry Co., Ltd. Tokyo, Japan. DU145 was seeded at a density of 1,700 cells/ well on 96-well plates (Sumitomo Bakelite Co., Ltd., Tokyo, Japan). The next day, DTX was added to each well at concentrations of 0, 0.4, 0.6, 0.8, 1 and 2 nM (final in 0.1% DMSO). After 3 days, the numbers of viable cells (Figure 2A ). Male nude BALB/c mice were purchased from Japan SLC Inc. (Shizuoka, Japan). The animals were housed in constant temperature and humidity conditions and fed a standard diet with water ad libitum. Our institutional animal care committee approved all animal experiments. Male nude mice were subcutaneously implanted with approximately 100 μl of 8×10 6 DU145 cells mixed with Matrigel™ Basement Membrane Matrix high Concentration (Matrigel™) (#354248; Corning, Tokyo, Japan) into the right flank. When the estimated tumor volume reached approximately 200 mm 3 , mice bearing established tumors were randomized into five treatment groups (vehicle; 1, 2.5, 5 and 10 mg/kg, DTX; n=6 for each group) with an almost equivalent average body weight. The mice were subcutaneously treated with each concentration of DTX in PEG300 once per week and observed for 26 days. The tumor volumes (V) were calculated by caliper measurements of the width (W) and length (L) of each tumor using the formula: V=W×W×L/2. Figure 2B ). Male nude mice were subcutaneously implanted with approximately 100 μl of 8×10 6 DU145 cells mixed with Matrigel™ into the right flank. The tumor was obtained from the mice and split into pieces (particle sizes of approximately 3 mm × 3 mm × 3 mm) and then subcutaneously implanted into 5-week-old nude mice. When the estimated tumor volume reached ca. 100 mm 3 , mice bearing established tumors were randomized into 8 treatment groups (vehicle; 0.1, 0.5, 0.75, 1.0, 2.5, 5.0 and 10 mg/kg DTX; n=5 for each group) with an almost equivalent average of body weight and tumor volumes. The mice were subcutaneously treated with each concentration of DTX in 0.5% methylcellulose (MC) for 32 days once per week. Tumor volumes and body weight were periodically measured. Animals were sacrificed after 32 days and the weights of the tumor, liver, kidney and spleen were measured. Blood was collected from the abdominal vein with heparin as an anticoagulant and the plasma was obtained by centrifugation. The concentrations of serum glutamic-oxaloacetic transaminase (GOT), glutamicpyruvic transaminase (GPT), creatinine and blood urea nitrogen (BUN) were measured using commercially available kits (Transaminase CII Test WAKO #431-30901, LabAssay Creatinine #290-65901, L type WAKO UN #410-55391 #416-55951; WAKO Pure Chemical Industries, Ltd., Osaka, Japan).
Xenograft model formed by implantation of a mixture of DU145 cells and Matrigel™

Xenograft model formed by implantation of a solid tumor of DU145 (
Statistical analysis.
The results are shown as the means±standard error (SE) of each group and were analyzed for statistical significance using Student's t-test compared with vehicle control.
Results
Inhibition of DU145 growth in vitro by DTX. The inhibitory activity of DU145 cell growth by DTX was estimated ( Figure  1 ). The IC 50 value was 1.1 nM in this study after 72 h of drug exposure, which was approximately in agreement with a previous report's IC 50 values of 0.47 nM (4) and 1.1 nM (5).
Suppression of xenograft DU145 tumor by DTX. There were two xenograft murine models bearing DU145 cells (Figure 2) . First, the inhibitory effect of DTX on DU145 tumor growth after subcutaneous implantation with DU145 cells mixed with Matrigel™ was examined (Figure 2A) . Vehicle or DTX (1, 2.5, 5 and 10 mg/kg) was subcutaneously administered once a week for 26 days and the tumor volume (mm 3 ), as well as body weight (g), were periodically measured ( Figure 3 ; Tables I, II and III) . The tumor growth was slower than control growth at doses of 1.0, 5.0 and 10 mg/kg DTX, though tumor growth was accelerated at 2.5 mg. Tumor sizes at 10 mg/kg DTX were significantly reduced within a few days (p<0.05 by Student's t-test). Interestingly, tumors in the 2.5 mg/kg DTX group were often filled with liquid matter, such as blood plasma and sometimes blood, while tumors at the other doses consisted of cells ( Figure 3D ). The body weights of mice were reduced ANTICANCER RESEARCH 37: xxx-xxx (2017) 2 almost dose-dependently, except with the administration of 2.5 mg of DTX; significance was observed in the 10 mg/kg group compared with control.
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Discussion
Inhibitory activities of DTX in DU145 xenograft mice were examined under two conditions (Figure 2A and 2B). DTX was subcutaneously injected for 26 days (Figure 3 ; Tables I,   II and III) or 32 days (Figure 4 ; Tables IV, V and VI), once per week, and the tumor volume and body weights were measured. In previously reported works, administration of 25 mg/kg DTX (intravenously (i.v.), 5 days/week, 6 weeks) completely suppressed DU145 tumor growth in a xenograft model (7), while, intraperitoneally (i.p.), at 10 mg/kg (once/week, 3 weeks), DTX partially inhibited the growth of DU145 tumors in a xenograft model (8) . Moreover, there are similar reports at a dose higher than 15 mg/kg in an interview (Sanofi Co. Ltd.) (5) and over 8.9 mg/kg elsewhere (9) . However, DTX is clinically used at a dose of almost 2-3 mg/kg (75 mg/m2) by infusion over 3 hours once every 3 weeks in Japan (5). According to our search, this is the first report to examine the dose-dependence of DTX at a wide range of doses on the inhibition of tumor growth in xenograft mice bearing DU145 tumors. DTX at 1, 5 and 10 mg/kg doses inhibited tumor growth in a xenograft model that was developed by the injection of DU145 cells (Figure 3) . However, suppression of tumor growth was not observed Figure 3D ), with tumor volume and body weight being higher. There is no precise explanation for this result except that DTX often causes edematous side-effects in clinical use (10) . The body weights of mice at 10 mg/kg DTX were reduced one week after DTX administration, which was maintained until the end. This observation could be due to the toxicities of DTX. Next, we estimated the inhibitory activities of DTX in xenograft mice developed by implantation of a solid tumor because the targets of DTX are usually solid tumors instead of individual cells (Figure 4) . In this study, a wide range of DTX doses of 0.1, 0.5, 0.75, 1, 2.5, 5 and 10 mg/kg was subcutaneously administered once a week for 32 days and tumor volume, as well as body weights, were measured ( Figure 4) . The inhibitory effects of DTX at 5 and 10 mg/kg were the strongest ( Figure 4A and 4B) . Interestingly, the suppression effects at 2.5 mg/kg were less than those at 0.1 mg/kg and with vehicle. Edema-like effects were noted in most bodies of mice with 2.5 mg/kg DTX ( Figure 4D) , with tumors being filled with blood serum and other liquid products ( Figure 3D, Figure 5 ). Again, the only known explanation for these edema-like effects is the edema sideeffects observed in clinical patients with the administration of DTX (5, 10) . The inhibitory activities in xenograft mice with solid tumors were weaker than for individual DU145 cells in Matrigel™ (Figures 3 and 4) . This difference is thought to be due to the difficulty to penetrate the solid DU145 tumor ( Figure 2B ).
The body weights of mice with the solid tumor model were also suppressed by the administration of 10 mg/kg DTX after 20 days ( Figure 4C ). However, the weights of the body, liver and kidney on the final day nearly matched the control levels ( Figure 5 ). Hypertrophy of the spleen was frequently noted in all conditions and its dose-dependence was unclear ( Figure  5 ). This could be an artificial result attributed to subcutaneous wounding of nude mice because this phenomenon has not been clinically reported. With respect to hematological parameters, the plasma GOT and GPT values were significantly low, except for with 0.1 mg/kg DTX ( Figure 6 ). These significant decreases did not indicate liver toxicity because the values are usually increased in toxic conditions. Plasma creatinine was normal under all conditions, while its value was only higher at the lowest dose ( Figure 6) ; the plasma BUN values were significantly higher ( Figure 6 ). Although an increase in the BUN is reported in the interview form on DTX (5), we do not have an explanation for this observation. The body weights of mice at a dose of 10 mg/kg were clearly suppressed for both xenograft models ( Figure 3C and 4C), with this effect being suspected to be a toxic sideeffect of DTX.
In conclusion, we performed a systematic trial on the inhibitory activities of DTX in two DU145 xenograft models 
t-test. Each value was estimated with commercially available kits (see the Materials and Methods section for details).
( Figure 2 ) and demonstrated that (i) DTX was more effective in the xenograft model formed by DU145 cell implantation than the model formed by solid DU145 tumor implantation ( Figures 3 and 4) ; (ii) administration of 2.5 mg/kg DTX was critical because the inhibitory activities of 2.5 mg/kg DTX and lower were weak, while DTX showed effective inhibitory activities at 5 and 10 mg/kg; (iii) edema-like effects were observed for both xenograft models at 2.5 mg/kg DTX with no clear explanation for this irregularity; and (iv) suppression of body weight gain was observed with 10 mg/kg DTX in both xenograft models. DTX is now a standard anti-cancer drug for first-line treatment of hormone-refractory prostate cancer cells. However, its clinical prescription is sometimes limited by edematous side-effects, causing, occasionally, severe edema (5, 11) . Based on these results, we believe that the 2.5 mg/kg DTX dose was critical in the xenograft model of DU145 tumor growth for evaluating anti-tumor effects and adverse events regarding combination treatments of new compounds leading, eventually, to a better selection of novel hormone-independent prostate cancer agents.
